About imatinibanticancer, tyrosine- kinase inhibitor, first generation.mechanism of action of imatinibimatinib is an inhibitor of multiple tyrosine kinases including kit, abl, and pdgfr( platelet-derived growth factor receptor) and inhibit phosphorelation.indications for imatinib1.chronic myelogenous leukemia 2.lymphoblastic leukemia (ph+all) 3.gastrointestinal stromal tumors 4.systemic mastocytosis 5.hypereosinophilic syndrome 6.dermatofibrosarcoma protuberans. 7.plexiform neurofibromas interactions for imatinibcyp3a4 inhibitors e.g. ketoconazole, erythromycin, clarithromycin, itraconazole, grapefruit juice)---- decrease metabolism---- increase imatinib exposure (40%) cyp3a4 inducers (dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or st. john?s wort)----- increase metabolism---- decrease imatinib exposure (74%) cyp2d6 inhibitors (e.g. doxorubicin, quinidine, vinca alkaloids, dextropropoxyphene)---- decrease metabolism---- increased